Recent Finacing
Recent Raise
Iceni Pharmaceuticals develops repurposed and reformulated cancer therapies, advancing cilengitide (Cilcane®) for multiple myeloma as combination therapy with proteasome inhibitors, holding formulation/methods IP and planning Phase II trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors